GSK (GSK) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Strategic transformation and growth

• Significant progress made since 2017, including a major shift to prioritize the pipeline and focus on vaccines and specialty medicines, now comprising two-thirds of the business.

• Achieved three years of competitive, profitable growth post-demerger, with a transformed balance sheet reducing debt from $29 billion to $12 billion.

• Upgraded outlooks for 2026 and 2031, projecting over GBP 38 billion in turnover by 2031, excluding potential from the Blenrep launch.

• Specialty business is currently the largest, growing at 20%, with double-digit growth in HIV, respiratory immunology, and oncology.

• Business development remains active, with 16 deals in recent years and continued focus on high-return, disciplined investments.

Innovation, pipeline, and technology

• Eleven positive phase 3 results this year, with five new launches expected by the end of next year.

• Strong momentum in oncology, especially with Blenrep, and ongoing expansion in vaccines, including mRNA and MAPS.

• Technology and AI are seen as transformative, impacting productivity, R&D, and healthcare access globally.

• External board experience, particularly at Microsoft, informs the integration of science, technology, and talent to drive innovation.

• AI is expected to revolutionize drug discovery, trial design, and healthcare delivery over the next decade.

Market dynamics and regulatory environment

• All impacts from U.S. Part D redesign and IRA have been factored into guidance, with GBP 400–500 million impact expected in 2025, mainly in specialty and HIV.

• Constructive engagement with U.S. regulators and policymakers, focusing on innovation access, PBM reform, and minimizing unintended consequences from IRA.

• $800 million investment committed in Marietta, Pennsylvania, reinforcing the U.S. as a key market for innovation and growth.

• Industry remains aligned on key policy themes and continues to advocate for predictable patient costs and expanded vaccine access.